Presentation of Phase 2 clinical trial results
Filed with ASX · · 16 pages · English
Paradigm Biopharmaceuticals Ltd. on 6ix
In the deck
Earlier from Paradigm Biopharmaceuticals
- PAR reports successful Phase 2 clinical trial
- Paradigm reports consistent OA pain reduction
- Paradigms AGM Presentation
- Paradigm in-licenses treatment for rare joint disease
- Paradigm receives $2.32m R&D tax incentive refund
Later from Paradigm Biopharmaceuticals
- Paradigms supplementary Phase 2B data
- Paradigms orphan Phase 2/3 clinical program progresses
- S&P DJI Announces March 2019 Quarterly Rebalance
- Paradigm (PAR) Updated Investor Presentation
- Paradigms secondary endpoints successfully met
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals